Background: Although amnestic mild cognitive impairment (aMCI) is generally considered to be a prodromal stage of Alzheimer's disease, patients with aMCI show heterogeneous patterns of progression. Moreover, there are few studies investigating data-driven cognitive trajectory in aMCI. We therefore classified patients with aMCI based on their cognitive trajectory, measured by clinical dementia rating sum of boxes (CDR-SOB). Then, we compared the clinical and neuroimaging features among groups classified by cognitive trajectory.

Methods: We retrospectively recruited 278 patients with aMCI who underwent three or more timepoints of neuropsychological testing. They also had magnetic resonance imaging (MRI) including structured three-dimensional volume images. Cortical thickness was measured using surface-based methods. We performed trajectory analyses to classify our aMCI patients according to their progression and investigate their cognitive trajectory using CDR-SOB.

Results: Trajectory analyses showed that patients with aMCI were divided into three groups: stable (61.8%), slow decliner (31.7%), and fast decliner (6.5%). Changes throughout a mean follow-up duration of 3.7 years in the CDR-SOB for the subgroups of stable/slow/fast decliners were 1.3-, 6.4-, and 12-point increases, respectively. Decliners were older and carried apolipoprotein E4 (APOE4) genotypes more frequently than stable patients. Compared with the stable group, decliners showed a higher frequency of aMCI patients with both visual and verbal memory dysfunction, late stage aMCI, and multiple domain dysfunction. In addition, compared with the stable group, the slow decliners showed cortical thinning predominantly in bilateral parietotemporal areas, while the fast decliners showed cortical thinning predominantly in bilateral frontotemporal areas. Both decliner groups showed worse cognitive function in attention, language, visuospatial, memory, and frontal/executive domains than the stable group.

Conclusions: Our data-driven trajectory analysis provides new insights into heterogeneous cognitive trajectories of aMCI and further suggests that baseline clinical and neuroimaging profiles might predict aMCI patients with poor prognosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343354PMC
http://dx.doi.org/10.1186/s13195-018-0462-zDOI Listing

Publication Analysis

Top Keywords

patients amci
16
cognitive trajectory
12
amci patients
12
amci
11
cognitive
9
patients
9
cognitive trajectories
8
amnestic mild
8
mild cognitive
8
clinical neuroimaging
8

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Ophthalmology, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea, Republic of (South).

Background: Spectrum Domain-Optical Coherence Tomography (SD-OCT) is a non-invasive technology that acquires cross-sectional images of retinal structures allowing neural fundus integrity assessment. Macular thickness and retinal nerve fiber layer (RNFL) thickness measured by an SD-OCT have been used as a indicator of Alzheimer's disease (AD) and amnestic mild cognitive impairment (aMCI). However which portion of retinal RNFL is the most sensitive area among normal control, aMCI and AD is not clear yet.

View Article and Find Full Text PDF

Background: About 20-30% of clinically diagnosed AD dementia patients do not meet pathologic criteria for AD and this proportion is even higher in amnestic MCI. Among tau-negative amnestic patients, limbic-predominant age-related TDP-43 encephalopathy (LATE) has been described as a principal diagnostic alternative, especially at advanced age. LATE is characterized by a specific temporo-limbic hypometabolic signature on FDG-PET that may aid in differential diagnosis.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Background: Synaptic dysfunction occurs in the early stages of neurodegenerative diseases and leads to the breakdown of connections within neuronal networks. Therefore, biomarkers reflecting this process, such as neurogranin (Ng), might be useful to study disease pathophysiology and aid in diagnostics. Ng is crucial for long-term potentiation and memory consolidation, and plays a central role in synaptic plasticity.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Linus Health, Boston, MA, USA.

Background: There is an urgent need for neuropsychological screening tests that are easily deployed and reliable. We have developed a digital neuropsychological screening protocol that is administered on a tablet, automatically scored using artificial intelligence, and requires approximately 10 minutes to administer. This tablet-administered protocol assesses the requisite neurocognitive constructs associated with emergent neurodegenerative illness METHOD: The digital protocol was administered to 77 ambulatory care/ memory clinic patients (Table 1).

View Article and Find Full Text PDF

Background: Neuroinflammation and activation of the immune system can influence Alzheimer's disease (AD) progression. This is mediated by inflammatory molecules, which exacerbate the production of β-amyloid, the propagation of tau pathology, and neuronal loss. By measuring CSF markers of inflammation in a heterogeneous clinical cohort we found that levels of Adenosine Deaminase (ADA) and Matrix-Metaloproteinase-10 (MMP-10) increase in patients with AD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!